Business Wire

Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019

Jaa

Incyte Corporation (Nasdaq:INCY) announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019. The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.

Accepted abstracts feature data from clinical studies involving Incyte’s anti-PD-1 monoclonal antibody, INCMGA00121, in patients with advanced solid tumors, as well as pre-clinical characterizations of the Company’s oral, small molecule PD-L1 inhibitor program and its PD-L1xCD137 bispecific antibody.

“Data accepted for presentation during the upcoming AACR Annual Meeting demonstrate our ongoing commitment to advancing innovative research as we seek to bring forward novel therapies for patients with cancer,” stated Dashyant Dhanak, Ph.D., Chief Scientific Officer, Incyte. “In particular, we are pleased to present, for the first time at a major medical meeting, early data on our oral PD-L1 inhibitor program—whose lead candidate, INCB86550, recently entered clinical trials.”

Key abstracts include:

Clinical

Pharmacodynamic correlates in a phase 1 study of INCMGA00012, a PD-1 antagonistic monoclonal antibody (Abstract #CT085/9, Phase 1 Clinical Trials: Part 3)

  • Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 16

Assessment of flat dosing strategy for INCMGA00012 in patients with advanced tumors (Abstract #LB-268/14, Late-Breaking Research: Experimental and Molecular Therapeutics)

  • Wednesday, April 3, 2019, 8:00 a.m. – 12:00 p.m. ET, Poster Section 40

Pre-Clinical

Oral Presentations

Novel small-molecule antagonists of the PD-1/PD-L1 axis that mediate cell surface PD-L1 dimerization and internalization (Abstract #4483, Novel Therapeutics)

  • Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m. ET, Georgia Ballroom 3 – Georgia World Congress Center (Building C)

Preclinical characterization of potent and selective oral PD-L1 small-molecule antagonists (Abstract #4480, Novel Therapeutics)

  • Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m. ET, Georgia Ballroom 3 – Georgia World Congress Center (Building C)

Poster Presentations

A bispecific Fc-silenced IgG1 antibody (MCLA-145 2 ) requires PD-L1 binding to activate CD137 (Abstract #539/3, Therapeutic Antibodies I)

  • Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 23

An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties (Abstract #541/5, Therapeutic Antibodies I)

  • Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 23

Characterization of human cancer cell line xenografts in humanized mice (Abstract #1050/1, Human in Mouse)

  • Monday, April 1, 2019, 8:00 a.m. – 12:00 p.m. ET, Poster Section 4

Full session details and data presentation listings for AACR 2019 can be found at: https://www.abstractsonline.com/pp8/#!/6812.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s development pipeline and its presentation plans for the upcoming AACR annual meeting, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ending December 31, 2018. Incyte disclaims any intent or obligation to update these forward-looking statements.

1 INCMGA0012 licensed from MacroGenics, Inc.
2 MCLA-145 development in collaboration with Merus, NV.

Contact information

Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Earth Networks and RIMES Announce Technical Collaboration to Benefit Member Government Weather Services27.3.2019 02:00:00 EETTiedote

Earth Networks, a global provider of weather intelligence, announced today it has partnered with the Regional Integrated Multi-Hazard Early Warning System for Africa and Asia (RIMES). The partnership will enable a multi-year collaboration program to enhance RIMES’ member state National Hydro-Meteorological Services (NMHS) capacity for early warning of severe weather. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Together, the two organizations are working to improve access to reliable weather information and early warning capabilities in Africa and Asia. By contributing on-the-ground insights from its weather and lightning networks, Earth Networks is providing critical hyperlocal data to RIMES to help regional NMHS close weather observation gaps in real-time and support more accurate forecasting. These technology enhancements will result in quicker warnings to the public before and during severe weather events. Earth Networks has years of experience

Huawei Rewrites the Rules of Photography with Groundbreaking HUAWEI P30 Series26.3.2019 19:04:00 EETTiedote

During an exclusive launch event today at the Paris Convention Center, Huawei Consumer Business Group (BG) unveiled the HUAWEI P30 and HUAWEI P30 Pro. The HUAWEI P30 Series builds on the HUAWEI P Series DNA in design and photography and is the company’s most advanced series of smartphone cameras. These devices feature the innovative HUAWEI SuperSpectrum Sensor, an optical SuperZoom Lens, a new HUAWEI Time of Flight (ToF) Camera, and enhanced optical and AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro capture incredible photos and videos in every scenario. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005752/en/ HUAWEI P30 Series (Photo: Business Wire) Richard Yu, CEO of Huawei Consumer BG, said, “the HUAWEI P30 Series is a fundamental breakthrough after decades of digital camera technology development; it will rewrite the rules and reshape everyone’s percepti

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism26.3.2019 18:01:00 EETTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential long-term risks of renal and cardiovascular complications that patients treated with conventional therapy may experience. Six-year results from the open-label long-term safety and efficacy RACE study were also announced. Data was presented at the Endocrine Society’s 2019 Annual Meeting (ENDO) from 23–26 March in New Orleans, Louisiana, USA. “Results from the Burden of Illness Global Survey in 13 countries reveal the extent of the impact hypoparathyroidism has on patients and their caregivers throughout their daily lives,” said John Bilezikian M.D., Professor of Medicine at the Columbia University Irving Medical Center, New York, NY, USA. “This offers important insights and enables us to take a more holistic approach in the management of these patients due to a greater understanding of the poten

LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development26.3.2019 17:58:00 EETTiedote

Veeva Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader in medical dermatology, selected Veeva Development Cloud applications to help drive end-to-end business processes across product development. The company will utilize the Vault Clinical, Vault RIM, and Vault Quality suites to unify drug development on a single cloud platform. With Veeva Development Cloud, LEO Pharma can bring together applications for clinical, regulatory, and quality for even greater efficiency and compliance throughout the product development lifecycle. “LEO Pharma R&D has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to continuously pioneer dermatology. This requires that we are able to drive science globally, whilst at the same time securing timely delivery on our pipeline,” said Kim Kjøller, executive vice president of global research and development at LEO Pharma. “Veeva Development Cloud gives us a unified platform that can enable us to maximize eff

Keio Plaza Hotel Tokyo Hosts Japanese Sword Culture, Armor Exhibition – “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans”26.3.2019 17:05:00 EETTiedote

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host a special exhibition entitled “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans” displaying beautiful Japanese swords and armor from April 25 (Thursday) to June 27 (Thursday), 2019 in the 3rd floor lobby of our Hotel. This exhibition is part of our series of cultural programs designed to introduce various aspects of Japanese culture to our guests visiting the Hotel from over 100 different countries around the world. Various precious and old swords and armor made during the Heian Period (794-1185) and other periods of Japanese history will be displayed, along with “tsuba” (Sword handle guards separating the handle from the blade) and other ornate sword fittings. On May 14, two masters of sword-drawing from Ryushin Shouchi School will give a live performance in the Main lobby from 5:00 p.m. This press release features multimedia. View the full release

Andersen Global Enters Qatar26.3.2019 16:30:00 EETTiedote

Andersen Global today announced a collaborating agreement in Qatar with Al-Khalifa Law, a leading Doha-based law firm. The collaboration is Andersen Global’s first in Qatar and is part of the organization’s continued growth in the Middle East. Al-Khalifa Law was founded 20 years ago and established itself as a premier firm in the region. The team at Al-Khalifa Law has diversified, deep experience providing services in a wide variety of business sectors, such as commercial contracts, taxation, employment, real estate and retail, intellectual property, dispute resolution and litigation and arbitration. “A collaboration with Andersen Global, which brings with it a culture of stewardship, transparency, and providing best-in-class services, was an obvious decision for us,” said Hamzeh Abdelhady, Office Managing Director of Al-Khalifa Law. “We will be able to continue providing quality services in the market and bring a premier, seamless association of experts throughout the world directly t

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme